利培酮对精神分裂症患者代谢影响的临床研究
发布时间：2018-10-08 18:02
【摘要】：目的： 1.探讨利培酮引发精神分裂症患者体重增加的特点及相关因素。 2.探讨利培酮对精神分裂症患者代谢指标的影响效应及相关因素。 方法： 第一部分对115例住院精神分裂症患者进行为期24周的利培酮治疗观察,每2周测量1次身高、体重及评估1次阳性与阴性症状量表以及食量、睡眠量、活动量的变化情况等。 第二部分 对56例住院精神分裂症患者予以利培酮治疗16周,每2周测量1次腰围、血压及评估1次阳性与阴性症状量表,入组后次日及8周末、16周末各测定1次空腹血糖、血脂及餐后2小时血糖等；并与36例健康者做对照。 结果： 第一部分 1.体重增加的发生率为61.74%(71例),其中91.55%发生在16周内：体重增加组的体重指数于4～12周快速上升,16周内上升幅度占总升幅的89.18%,20周后不再显著性上升(P0.05)。 2.影响体重指数上升率的因素为用药史、肥胖家族史、食量变化、基线体重指数。 第二部分 1.患者组治疗后腰围、甘油三酯、餐后2小时血糖较治疗前显著性上升,高密度脂蛋白显著性降低,变化值与对照组比较差异有显著性(P0.05)；血压、空腹血糖治疗前后差异无显著性(P0.05)。 2.患者组代谢综合征的发生率为12.50%(7例),腰围、甘油三酯、高密度脂蛋白及餐后2小时血糖异常率分别为39.29%、21.43%、12.50%及19.64%,与对照组比较均差异有显著性(P0.05)；血压、空腹血糖异常率分别为8.93%及5.36%,与对照组比较差异无显著性(P0.05)。3.发生代谢综合征的危险因素为糖尿病家族史及年龄,发生腰围超标、甘油三酯异常、餐后2小时血糖异常的危险因素分别为基线腰围及肥胖家族史、基线甘油三酯及基线收缩压、基线腰围及年龄。 结论： 第一部分 1.利培酮可引发精神分裂症患者普遍的体重增加,集中出现在用药后的前4个月；体重上升在前3个月最快、至少持续半年。 2.未用过抗精神病药物、有肥胖Ⅰ级家族史、用药后食量明显增多及体型偏瘦的精神分裂症患者,接受利培酮治疗后易发生体重增加。 第二部分 1.利培酮可引发精神分裂症患者腹型肥胖和糖脂代谢紊乱乃至代谢综合征。 2.对年龄大、有糖尿病Ⅰ级家族史及体态较胖的精神分裂症患者,应慎用利培酮。
[Abstract]:Objective: 1. To investigate the characteristics and related factors of weight gain in patients with schizophrenia induced by risperidone. 2. To investigate the effect of risperidone on metabolic indexes in schizophrenic patients and its related factors. Methods: in the first part, 115 inpatients with schizophrenia were treated with risperidone for 24 weeks. Height, weight, positive and negative symptom scale, food intake, sleep volume were measured once every 2 weeks. A change in activity, etc. In the second part, 56 inpatients with schizophrenia were treated with risperidone for 16 weeks, waist circumference was measured once every 2 weeks, blood pressure and positive and negative symptoms were evaluated once. Fasting blood glucose, blood lipids and 2 hours postprandial blood glucose were measured once on the next day and at the 16th weekend of the 8th weekend, respectively, and were compared with 36 healthy subjects. Results: part 1. The incidence of body weight gain was 61.74% (71 cases), of which 91.55% occurred within 16 weeks. The body mass index (BMI) of the weight gain group increased rapidly at 4 ~ 12 weeks and accounted for 89.18% of the total increase within 16 weeks (P0.05). 2. The factors influencing the increase of BMI were the history of medication, family history of obesity, changes of food intake and baseline BMI. Part 1. After treatment, the waist circumference, triglyceride, 2 hours postprandial blood glucose in the patients group were significantly higher than those before treatment, and the HDL level was significantly lower than that in the control group (P0.05), blood pressure, blood pressure, There was no significant difference in fasting blood glucose before and after treatment (P0.05). 2. The incidence of metabolic syndrome was 12.50% (7 cases). The abnormal rates of waist circumference, triglyceride, high density lipoprotein and 2 hours postprandial blood glucose were 39.29 and 21.43%, 12.50% and 19.64, respectively. The abnormal rates of fasting blood glucose were 8.93% and 5.36%, respectively. There was no significant difference compared with the control group (P0.05). 3. The risk factors of metabolic syndrome were family history and age of diabetes mellitus, excess waist circumference, abnormal triglyceride and 2 hours postprandial blood glucose abnormality. The risk factors of metabolic syndrome were baseline waist circumference and family history of obesity. Baseline triglyceride and baseline systolic blood pressure, baseline waist circumference and age. Conclusion: part 1. Risperidone can trigger general weight gain in schizophrenic patients, concentrated in the first four months after medication; weight gain is fastest in the first three months, lasting at least half a year. 2. Patients with schizophrenia who had not used antipsychotic drugs and had a family history of obesity grade 鈪，
本文编号：2257744
[Abstract]:Objective: 1. To investigate the characteristics and related factors of weight gain in patients with schizophrenia induced by risperidone. 2. To investigate the effect of risperidone on metabolic indexes in schizophrenic patients and its related factors. Methods: in the first part, 115 inpatients with schizophrenia were treated with risperidone for 24 weeks. Height, weight, positive and negative symptom scale, food intake, sleep volume were measured once every 2 weeks. A change in activity, etc. In the second part, 56 inpatients with schizophrenia were treated with risperidone for 16 weeks, waist circumference was measured once every 2 weeks, blood pressure and positive and negative symptoms were evaluated once. Fasting blood glucose, blood lipids and 2 hours postprandial blood glucose were measured once on the next day and at the 16th weekend of the 8th weekend, respectively, and were compared with 36 healthy subjects. Results: part 1. The incidence of body weight gain was 61.74% (71 cases), of which 91.55% occurred within 16 weeks. The body mass index (BMI) of the weight gain group increased rapidly at 4 ~ 12 weeks and accounted for 89.18% of the total increase within 16 weeks (P0.05). 2. The factors influencing the increase of BMI were the history of medication, family history of obesity, changes of food intake and baseline BMI. Part 1. After treatment, the waist circumference, triglyceride, 2 hours postprandial blood glucose in the patients group were significantly higher than those before treatment, and the HDL level was significantly lower than that in the control group (P0.05), blood pressure, blood pressure, There was no significant difference in fasting blood glucose before and after treatment (P0.05). 2. The incidence of metabolic syndrome was 12.50% (7 cases). The abnormal rates of waist circumference, triglyceride, high density lipoprotein and 2 hours postprandial blood glucose were 39.29 and 21.43%, 12.50% and 19.64, respectively. The abnormal rates of fasting blood glucose were 8.93% and 5.36%, respectively. There was no significant difference compared with the control group (P0.05). 3. The risk factors of metabolic syndrome were family history and age of diabetes mellitus, excess waist circumference, abnormal triglyceride and 2 hours postprandial blood glucose abnormality. The risk factors of metabolic syndrome were baseline waist circumference and family history of obesity. Baseline triglyceride and baseline systolic blood pressure, baseline waist circumference and age. Conclusion: part 1. Risperidone can trigger general weight gain in schizophrenic patients, concentrated in the first four months after medication; weight gain is fastest in the first three months, lasting at least half a year. 2. Patients with schizophrenia who had not used antipsychotic drugs and had a family history of obesity grade 鈪，
本文编号：2257744
本文链接：https://www.wllwen.com/yixuelunwen/jsb/2257744.html
最近更新
教材专著
